Anxiety, Bipolar, Depressive, and Schizophrenia Diagnoses Among Patients Receiving Addiction Treatment in the United States, 2006-2022: A Descriptive Study

BACKGROUND: This study examined specific mental health diagnoses groupings among patients admitted to specialty addiction treatment in the United States from 2006 to 2022. METHODS: Joinpoint regression was used to examine annual data from the publicly available Treatment Episode Data Set - Admissions. Sample selection criteria included having a primary substance listed and any of the following conditions: (a) anxiety disorders, (b) bipolar disorders, (c) depressive disorders, and (d) schizophrenia and other psychotic disorders. RESULTS: Prior to sample selection, across the full dataset of 31 152 649, cases with anxiety disorders accounted for 0.1%, bipolar disorders accounted for 0.3%, depressive disorders accounted for 0.4%, and schizophrenia and other psychotic disorders accounted for 0.1%. The total sample size was N = 224 051 with: (a) 13% for anxiety disorders (n = 29 111), (b) 30.3% for bipolar disorders (n = 67 926), (c) 43.4% for depressive disorders (n = 97 293), and (d) 13.3% for schizophrenia and other psychotic disorders (n = 29 721). Count data identified significant decreases including the following: 12.29% from 2008 to 2022 among the bipolar disorder group, 16.69% from 2019 to 2022 among the depressive disorder group, and 6.96% from 2006 to 2022 among the schizophrenia and other psychotic disorders group. CONCLUSION: This study has important implications for future research and clinical care related to co-occurring mental health and substance use disorders. Its findings demonstrate the need for further studies to examine how addiction treatment facilities are screening for and recording mental health disorder diagnoses. Future research is needed to clarify the prevalence of specific mental health diagnoses in the addiction treatment setting, including diagnoses such as anorexia nervosa and generalized anxiety disorder. This research would help determine specific treatment needs by using epidemiological data to provide a snapshot of the prevalence of these co-occurring conditions.

Authors

Institutions

Publication Details

Journal
Substance Use &amp Addiction Journal
Published
2026-05-10
DOI
https://doi.org/10.1177/29767342261445244
Primary Topic
Substance Abuse Treatment and Outcomes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Anxiety, Bipolar, Depressive, and Schizophrenia Diagnoses Among Patients Receiving Addiction Treatment in the United States, 2006-2022: A Descriptive Study

Mark P. McGovern, Orrin D. Ware, David A. Fiellin
Substance Use &amp Addiction Journal
Substance Abuse Treatment and Outcomes
article

Anxiety, Bipolar, Depressive, and Schizophrenia Diagnoses Among Patients Receiving Addiction Treatment in the United States, 2006-2022: A Descriptive Study

Mark P. McGovern, Orrin D. Ware, David A. Fiellin
article en

Abstract

BACKGROUND: This study examined specific mental health diagnoses groupings among patients admitted to specialty addiction treatment in the United States from 2006 to 2022. METHODS: Joinpoint regression was used to examine annual data from the publicly available Treatment Episode Data Set - Admissions. Sample selection criteria included having a primary substance listed and any of the following conditions: (a) anxiety disorders, (b) bipolar disorders, (c) depressive disorders, and (d) schizophrenia and other psychotic disorders. RESULTS: Prior to sample selection, across the full dataset of 31 152 649, cases with anxiety disorders accounted for 0.1%, bipolar disorders accounted for 0.3%, depressive disorders accounted for 0.4%, and schizophrenia and other psychotic disorders accounted for 0.1%. The total sample size was N = 224 051 with: (a) 13% for anxiety disorders (n = 29 111), (b) 30.3% for bipolar disorders (n = 67 926), (c) 43.4% for depressive disorders (n = 97 293), and (d) 13.3% for schizophrenia and other psychotic disorders (n = 29 721). Count data identified significant decreases including the following: 12.29% from 2008 to 2022 among the bipolar disorder group, 16.69% from 2019 to 2022 among the depressive disorder group, and 6.96% from 2006 to 2022 among the schizophrenia and other psychotic disorders group. CONCLUSION: This study has important implications for future research and clinical care related to co-occurring mental health and substance use disorders. Its findings demonstrate the need for further studies to examine how addiction treatment facilities are screening for and recording mental health disorder diagnoses. Future research is needed to clarify the prevalence of specific mental health diagnoses in the addiction treatment setting, including diagnoses such as anorexia nervosa and generalized anxiety disorder. This research would help determine specific treatment needs by using epidemiological data to provide a snapshot of the prevalence of these co-occurring conditions.

Substance Use &amp Addiction Journal
University of North Carolina at Chapel Hill (US), New Haven Public Schools (US), Yale University (US), Stanford Medicine (US)
National Institute on Drug Abuse
Good health and well-being
Openalex Percentile: Top 5%
Substance Abuse Treatment and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.